ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

Biosimilars to Raise Unique Questions

  |  

Rheumatologists are accustomed to educating patients about medications, but biologic medications—and now biosimilars—require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. The first FDA-approved biosimilar to become…

Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases

  |  

WASHINGTON, D.C.—Patients with juvenile rheumatic diseases are thriving in an era of highly effective therapies, successful self-management strategies, better understanding of genetic links to autoimmunity risk and improved efforts to listen to and engage with these young patients. That bright picture for young people with arthritis was presented by pediatrics at the ACR/ARHP Concurrent Abstract…

Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis

  |  

WASHINGTON, D.C.—The vast majority of the attention given to vasculitis at the ACR/ARHP Annual Meeting, year after year, focuses on ANCA-associated vasculitis and large-vessel vasculitis, said Philip Seo, MD, MHS, director of the Johns Hopkins Vasculitis Center and moderator of the 2016 ACR Review Course titled, Neglected Vasculitis. That leaves out a lot. “These are…

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

  |  

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

  |  

The ACR has released a statement, responding positively to the release of the latest U.S. Food and Drug Administration (FDA) draft guidance on biosimilar drug development. Also, BI 695501, a biosimilar to Humira (adalimumab) made by Boehringer Ingelheim, has been accepted for regulatory review in both the U.S. and Europe. ACR Responds to FDA Biosimilar…

Rheumatology Coding Question: Deconstructing Evaluation and Management Codes

  |  

A 50-year-old male patient returns to the office for a follow-up visit for a diagnosis of generalized primary osteoarthritis of multiple sites. The patient tells the medical assistant that he is experiencing sharp throbbing pain in his left hip and right and left knees. He states the pain level is 6 out of 10 and…

Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD

Reuters Staff  |  

NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…